• 1
    Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.
  • 2
    Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 3
    Ku GY, Ilson DH. Role of neoadjuvant therapy for esophageal adenocarcinoma. Surg Oncol Clin N Am. 2009; 18: 533-546.
  • 4
    Cunningham D, Allum W, Stenning SP, et al; MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006; 355: 11-20.
  • 5
    Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long term results of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27: 5062-5067.
  • 6
    Van der Gaast A, van Hagen P, Hulshof M, et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric cancer; results from a multicenter randomized phase III study. J Clin Oncol. 2010; 28( 18 suppl): (abstract 4004).
  • 7
    Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Australasian Gastro-Intestinal Trials Group Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet. 2007; 8: 226-234.
  • 8
    Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009; 27: 851-856.
  • 9
    Adelstein DJ, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol. 2000; 18: 2032-2039.
  • 10
    Brenner B, Ilson D, Minsky B, et al. Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol. 2004; 22: 45-52.
  • 11
    Safran H, Gaissert H, Akerman P, et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest. 2001; 19: 1-7.
  • 12
    Bains MS, Stojadinovic A, Minsky B, et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg. 2002; 124: 270-277.
  • 13
    Ilson DH, Bains M, Kelsen DP, et al. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer. J Clin Oncol. 2003; 21: 2926-2932.
  • 14
    Knox JJ, Wong R, Visbal L, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery, for esophageal cancer. Cancer. 2010; 116: 4023-4032.
  • 15
    Kleinberg L, Powell ME, Forastiere AA, et al. Survival outcome of E1201: An Eastern Cooperative Oncology Group (ECOG) randomized phase II trial of neoadjuvant preoperative paclitaxel/cisplatin/radiotherapy (RT) or irinotecan/cisplatin/RT in endoscopy with ultrasound (EUS) staged esophageal adenocarcinoma. J Clin Oncol. 2008; 26:(abstract 4532).
  • 16
    Ajani JA, Correa AM, Walsh GL, et al. Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. Cancer. 2010; 116: 1656-1663.
  • 17
    Meluch AA, Greco FA, Gray JR, et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J. 2003; 9: 251-260.
  • 18
    Urba SG, Orringer MB, Ianettonni M, Hayman JA, Satoru H. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer. 2003; 98: 2177-2183.
  • 19
    Heath EI, Burtness BA, Heitmiller RF, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol. 2000; 18: 868-876.
  • 20
    Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared to radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326: 1593-1598.
  • 21
    Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001; 19: 3058-3065.
  • 22
    Downey RJ, Akhurst T, Ilson D, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003; 21: 428-432.
  • 23
    Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of esophagogastric junction. J Clin Oncol. 2006; 24: 4692-4698.
  • 24
    Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol. 2007; 8: 797-805.
  • 25
    Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N. A controlled trial of an expansile metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med. 1993; 329: 1302-1307.
  • 26
    Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A3rd. Neoadjuvant chemotherapy plus concurrent chemotherapy and high dose radiotherapy for squamous cell carcinoma of the esophagus: preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol. 1996; 14: 149-155.